Trial
NCT03430063
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Regeneron Pharmaceuticals
Collaborators
Sanofi
Condition
Advanced Non-Small Cell Lung Carcinoma
Intervention
SDREGN2810
Why stopped
Business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-03